Optimizing dolutegravir-based ART for children and teens with HIV
Official title: Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents
Funded at University of Florida · NIH-11575529 · Data updated 2026-11-12
This grant tests better dosing and regimens of dolutegravir for kids and adolescents with HIV to improve health outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | August 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $139,260 |
| NIH project number | 3R01AI186847-03S1 |
| Project ID | NIH-11575529 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents living with HIV who are receiving or may receive dolutegravir-based ART.
✕Less likely to help
Adults beyond the pediatric/adolescent age range or those not using dolutegravir-based ART may not benefit from this specific pediatric-focused work.
What this research studies
Children living with HIV have been slower to access newer treatments, and this project aims to address gaps in how dolutegravir-based ART works for them. Researchers will examine weight-based dosing, potential drug interactions, and pediatric formulations to ensure safer, more effective therapy. The work involves analyzing existing data and conducting targeted studies to improve how DTG is used in people from infancy through young adulthood. The goal is to make ART easier to take, with fewer side effects and better viral suppression for children and adolescents.
Why it matters
Potential benefit: If successful, the project could lead to more effective and easier-to-take HIV treatment regimens for children and adolescents, improving survival and quality of life.
How similar studies have gone: Previous pediatric DTG data suggest potential benefits, but more pediatric-specific dosing and safety data are still needed; this study builds on that foundation.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Kwara, Awewura Jacob — University of Florida
- Study coordinator: Kwara, Awewura Jacob
Related research
Other NIH-funded projects on the same topics.
-
Mitochondrial pores and muscle loss in cancer cachexia
A small US-based study will explore how changes in mitochondria contribute to muscle wasting in people with cancer cachexia and how this may be slowed.
-
Photobiomodulation for jaw pain from TMD
A clinician-scientist at the University of Florida is testing a light-based therapy to help adults with temporomandibular disorder pain feel better and jaw function improve.
-
How the brain controls swallowing and airway protection
A research team at the University of Florida is studying how brain networks control swallowing to reduce risk of choking and lung infections in people with neuromuscular diseases.
-
Donor-driven 3D organoid platform to study pancreatic cancer drug response
A pilot project to create patient-derived, 3D organoid models of pancreatic cancer to measure how tumors from different people respond to chemotherapy.
-
RAAS inhibitors and pancreatic cancer risk in diverse adults
A Florida-based study will look at whether commonly used blood pressure medicines (RAAS inhibitors) are linked to new cases of pancreatic cancer, especially among Black and Hispanic adults.
-
Pilot project exploring new cancer drugs for pancreatic cancer in African American patients
A small, early-stage project tests new drug-derived compounds to treat pancreatic cancer, focusing on African American patients who are disproportionately affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.